Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2000, p. 139-142, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Effect of Zinc-Reversible Growth-Inhibitory
Activity in Human Empyema Fluid on Antibiotic Microbicidal
Activity
Peter G.
Sohnle* and
Beth L.
Hahn
Division of Infectious Diseases, Department
of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, and the Research Service, VA Medical Center, Milwaukee, Wisconsin 53295
Received 3 March 1999/Returned for modification 23 June
1999/Accepted 22 October 1999
 |
ABSTRACT |
Abscess fluid supernatants have zinc-reversible microbial
growth-inhibitory activity that is mediated by calprotectin, a
zinc-binding protein. Because it inhibits microbial growth, this
activity might interfere with killing by antibiotics that require their
target organisms to be proliferating. In the present study, we cultured bacteria in human empyema fluid and used zinc to overcome the growth-inhibitory effect of calprotectin. We then compared the effect
of zinc on killing by the beta-lactams ampicillin and cefazolin with
that of the fluoroquinolone trovafloxacin, since the latter may be
better able to kill nonproliferating organisms. In empyema fluid
diluted 1:5 in normal saline, addition of zinc (30 µM) increased growth of two strains of Staphyloccocus aureus and two
strains of Escherichia coli but did not affect the MICs or
MBCs of the three antibiotics in Mueller-Hinton broth. For one strain
of S. aureus, no effect of zinc was found on killing by
either ampicillin or cefazolin. However, with the other strain of
S. aureus and both strains of E. coli,
significant enhancement of killing by both drugs was observed with zinc
addition. On the other hand, no effect on the killing of any of the
organisms was observed for trovafloxacin when zinc was added. These
results suggest that the zinc-reversible growth-inhibitory activity of
abscess fluid may interfere with the microbicidal activity of
antibiotics requiring proliferating target organisms, although
antibiotics better able to kill nonproliferating organisms may be less
affected by this phenomenon.
 |
INTRODUCTION |
Microorganisms require metals, such
as iron and zinc, for growth. Sequestration of these metal ions by host
metal-binding proteins can be an effective means of antimicrobial
defense. This mechanism has been described primarily as a system
involving host iron-binding proteins, such as lactoferrin and
transferrin (7, 25). However, a similar mechanism that is
based on zinc rather than iron has recently been described
(17). The substance responsible for this antimicrobial
effect is the calcium- and zinc-binding protein complex called
calprotectin; alternative names for this complex include the L1
protein, MRP 8 and MRP 14, calgranulin A and B, and the cystic fibrosis
antigen (6). Calprotectin appears to originate in the
cytoplasm of neutrophils and is then released at sites of infection as
these cells die and lyse; this protein has microbistatic activity
against a variety of bacterial and fungal microorganisms (13, 18,
21). Abscess fluid supernatants have been shown to contain large
amounts of calprotectin and to possess similar antimicrobial activity
(19). In fact, purification studies have demonstrated that
calprotectin accounts for almost all of the antimicrobial activity in
abscess fluid supernatants (15).
Several studies have shown that the growth-inhibitory effect of abscess
fluid supernatants or purified calprotectin is completely reversible
when micromolar quantities of zinc ions are added to the medium
(13, 15, 19). Calprotectin has been shown to directly bind
zinc (19), and other studies suggest that the protein is
competing with microorganisms for this metal (5, 16, 20).
The antimicrobial activity of this protein is primarily microbistatic,
although it does have microbicidal activity under certain circumstances
(12, 21).
Some antibiotics, particularly those of the beta-lactam class, are most
active against rapidly growing organisms. Because of its microbistatic
activity in abscess fluids, calprotectin could interfere with the
microbicidal activity of these antibiotics when they are used to treat
infections that are complicated by abscesses. Indeed, Bamberger et al.
have demonstrated that abscess fluid supernatants interfere with the
ability of cefazolin to kill Staphylococcus aureus, but if
zinc is added to reverse the growth-inhibitory effects of calprotectin,
then killing proceeds normally (3). Thus, calprotectin
appears to compromise the microbicidal effect of beta-lactam
antibiotics by suppressing growth of the target microorganisms.
In contrast to the beta-lactams, quinolone antibiotics have activity in
both the logarithmic and stationary phases of microbial growth, at
least against certain microorganisms (26). There is also
some evidence to suggest that this class of antibiotics may be
relatively more effective in killing microorganisms in abscesses
(4). The present study was undertaken to confirm the effects
of calprotectin on microbial killing by beta-lactam antibiotics and to
determine whether or not the fluoroquinolone antibiotic trovafloxacin
is similarly affected.
 |
MATERIALS AND METHODS |
Calprotectin-containing fluids.
A specimen of human pleural
empyema fluid obtained before the patient had been treated with
antibiotics was used for these studies. The fluid was centrifuged at
1,500 × g for 40 min and then at 38,000 × g for 30 min before further use. Protein concentration was
determined by a dye-binding assay (Bio-Rad Laboratories, Richmond, Calif.) to be 143 mg/ml for the undiluted fluid.
Antimicrobial agents.
These studies used ampicillin and
cefazolin from Sigma (St. Louis, Mo.) and trovafloxacin from Pfizer.
The compounds were solubilized and diluted according to standard
procedures. Fresh solutions were made for each experiment.
Microorganisms.
We used four microbial strains for most of
the studies. These included ATCC isolates 29213 and 25923 of S. aureus and ATCC isolate 25922 and a local clinical isolate (LCI)
of Escherichia coli.
MICs and MBCs.
We carried out microtiter plate MIC and
minimal bactericidal concentration (MBC) determinations with a
modification of standard methods (9). Doubling dilutions of
the different antibiotics, from 0.01 to 32 µg/ml in 0.1-ml volumes of
Mueller-Hinton broth, were tested with inocula of either
105 or 103 organisms per ml. Since we
previously found the effect of calprotectin to be inoculum dependent,
the 103 inoculum size was used in the experiments with
antibiotics and abscess fluids. After incubation at 37°C for 18 h, the lowest dilution of antibiotic that visibly inhibited growth was
taken as the MIC. After this incubation period, the samples without growth were streaked onto Trypticase soy agar and incubated for another
18 to 24 h. The MBC was taken as the lowest drug concentration that reduced growth by
99.9%.
Microtiter plate antagonism assay.
The organisms were
inoculated into 0.1-ml volumes of human empyema fluid diluted 1:5 in
normal saline; various concentrations of antibiotics were added, and
the samples were incubated for 18 h at 37°C. No other nutrients
were added; the empyema fluid itself served as the growth medium. The
inoculum used was 103 CFU per sample. At the end of the
incubation period, the contents of the wells (0.1 ml) were removed,
streaked on Trypticase soy agar, and cultured for 18 to 24 h, and
the number of resulting colonies were counted. In parallel samples, 30 µM ZnSO4 was added to the initial cultures to reverse the
growth-inhibiting effects of calprotectin. Comparisons were made
between the samples containing zinc and those that did not. Several
concentrations of each antibiotic were tested in doubling dilutions
around the expected MBCs in preliminary experiments; two or three
appropriate antibiotic concentrations were then used in the final
experiments with the concentration yielding a number of colonies
closest to that of the original inoculum, but numbering at least 10, which was then compared to its zinc-containing pair for the number of
colonies remaining.
Evaluation of data.
To determine statistical significance,
MICs and MBCs for zinc-containing samples were compared to control
samples with the unpaired t test. Results of the assays with
empyema fluid were expressed as the number of colonies remaining at the
appropriate antibiotic concentration for samples containing or not
containing zinc. Results were compared in these pairs with the single
sample t test. Significance of the determinations was taken
at a P value of <0.05.
 |
RESULTS |
MIC and MBC data were obtained for each of the two isolates of
both S. aureus and E. coli. The MBC data are
given in Table 1 and were generally
within 1 to 2 dilutions of the MICs (data not shown). MBCs were
determined with a standard high inoculum (105 organisms)
and a lower inoculum (103 organisms), with the latter
usually yielding smaller MBCs. As discussed above, the 103
inoculum size was used in the experiments with antibiotics and abscess
fluids because the effect of the latter is inoculum dependent. Because
zinc was used in later experiments to stimulate microbial growth in the
presence of empyema fluid, we determined the effect of this metal on
the MICs or MBCs of the drugs in standard media. As is also shown in
Table 1, none of the MBCs between control and zinc-containing samples
were significantly different. The same was also found for the MICs
(data not shown). Therefore, zinc alone did not appear to affect the
MICs or MBCs of the antibiotics in standard media for any of the four
organisms tested.
The effect of zinc on antibiotic microbicidal activity in abscess fluid
was tested with organisms grown directly in human empyema fluid diluted
1:5 in saline (final total protein concentration, 28.6 mg/ml).
Different antibiotic concentrations were tested, with results from the
concentration yielding a number of CFU closest to the original inoculum
after incubation being compared for samples with and without added
zinc. In the absence of antibiotic, zinc produced increased growth of
the organisms in empyema fluid, although the amount of growth
stimulation varied with the bacterial isolates (Table
2). With one isolate of S. aureus, 29213, such increases were found for samples containing
each of the three antibiotics, as shown in Table 2. However, for the
second isolate of S. aureus and the two isolates of E. coli, the numbers of CFU remaining in the samples with either
cefazolin or ampicillin were significantly decreased when zinc had been
added to the samples, as is also shown in Table 2. Presumably, the
increase in growth caused by zinc addition made the organisms more
susceptible to the microbicidal activity of the two beta-lactam
antibiotics. On the other hand, addition of zinc did not
significantly decrease the number of organisms remaining in the
trovafloxacin-containing samples for any of the isolates tested, as is
also shown in Table 2. There did not appear to be a clear relationship
between the stimulation of growth and the resulting enhancement of
antibiotic microbicidal activity; the isolate yielding the highest
stimulation with zinc was the S. aureus isolate that did not
show the increased killing effect when zinc was added.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Enhancement of antibiotic microbicidal activity
associated with zinc stimulation of microbial growth in
empyema fluida
|
|
 |
DISCUSSION |
In these studies, addition of zinc increased bacterial growth in
human empyema fluid, an effect that has previously been related to
overcoming the zinc-binding antimicrobial activity of calprotectin in
such fluid (19, 20). On the other hand, in the present study
addition of zinc did not affect the MICs or MBCs of the three
antibiotics in Mueller-Hinton broth. For one strain of S. aureus, no reductions of CFU were observed for any of the
antibiotics when zinc was added; however, with the other isolate of
S. aureus and the two isolates of E. coli,
addition of zinc significantly decreased the number of CFU present in
the cefazolin- and ampicillin-containing samples. In contrast, no
significant reductions in CFU of any of the organisms were observed for
samples containing trovafloxacin when zinc was added. Therefore, under
the conditions of these experiments, stimulation of bacterial growth by
addition of zinc appeared to enhance the killing ability of the two
beta-lactam antibiotics, but not that of the fluoroquinolone, trovafloxacin.
Antibiotics are known to work poorly in abscesses. Often this type of
infection will persist for long periods unless the abscesses are
drained (14). Neutrophils appear to localize less well to chronic abscesses than to acute ones (1). The presence of
abscesses appears to inhibit the bactericidal activity of blood
neutrophils, and the abscess fluid milieu is inhibitory to neutrophil
function (2). In addition, it has been found that there is a
poorly responsive subpopulation of neutrophils in abscess cell
populations and that these cells contain higher numbers of
abscess-derived bacteria (10). There are a variety of
substances and conditions in abscess fluids that may interfere with the
activity of various antibiotics, including beta-lactamases, DNA, and
acidic pH (4). It is also likely that the nondividing state
of the infecting microorganisms in abscesses may be at least partly at
fault. This effect of the abscess fluid milieu may be the result of an
active process involving sequestration of zinc by the neutrophil
protein calprotectin. It is possible that other factors relevant to
chronic infections may prevent the organisms from proliferating, but as demonstrated by Bamberger et al. (3) and confirmed by the
present studies, addition of zinc to abscess fluid supernatants will
stimulate bacterial growth in them.
Beta-lactam antibiotics are definitely better at killing proliferating
organisms than nonproliferating ones. For example, although group A
streptococci are known to be exquisitely sensitive to penicillin, this
drug is sometimes relatively ineffective in treating infections caused
by them (23). Stevens et al. have demonstrated better
results with drugs like clindamycin and erythromycin that do not depend
on the proliferation of the organisms for their microbicidal effects
(22). In a follow-up study, this group demonstrated the loss
of penicillin-binding proteins 1 and 4 in stationary-phase streptococci
(24); this finding may explain why beta-lactam drugs require
rapidly growing organisms for their microbicidal effects to be
manifested. Microbistatic drugs, such as tetracycline, may show
antagonistic effects in assays of the microbicidal activity of
beta-lactam antibiotics. Tetracycline has been reported to interfere
with the efficacy of penicillin therapy for bacterial meningitis
(11). As discussed above, the fluoroquinolone class of
antibiotics appears to have better activity against stationary-phase
antibiotics than does the beta-lactam class. Trovafloxacin, the agent
used in the present studies, is a drug of this class that has a greater
spectrum of activity against gram-positive and anaerobic bacteria than
the earlier fluoroquinolone drugs (8).
There may be a variety of reasons why bacteria stop or slow the rate of
their proliferation after the initial acute phase of an infection
passes. These may involve depletion of needed nutrients, including
metals or other substances, accumulation of toxic by-products within
enclosed spaces, or damage from various host defense mechanisms. Within
abscesses, zinc deprivation appears to be a major factor in suppressing
bacterial growth. The present studies demonstrate that stimulation of
growth in empyema fluid supernatants by addition of zinc enhances the
bactericidal activity of the two beta-lactam antibiotics tested but
does not have the same effect on the fluoroquinolone trovafloxacin. The
latter drug is probably killing the organisms at a maximal rate even
though they are zinc deprived and not proliferating actively. It is
possible that this antibiotic may kill bacteria efficiently in
infections complicated by abscesses, as has previously been shown for
ciprofloxacin in other studies (4, 26).
In the present study, the results involving zinc and the beta-lactam
drugs appeared to be concentration dependent inasmuch as high
concentrations (two to four times the value yielding the initial
inoculum) of each antibiotic would kill the organisms even without
addition of zinc, and low concentrations (a half or quarter of the
value yielding the initial inoculum) would not induce killing even when
zinc was added (data not shown). In addition, the effect was also
isolate dependent since the one isolate of S. aureus
appeared to behave differently from the other bacterial isolates. In
addition, these experiments did not show a definite relationship
between stimulation of growth by zinc and enhancement of killing by the
beta-lactam antibiotics. In fact, the one isolate of S. aureus that did not show increased susceptibility to ampicillin and cefazolin in empyema fluid with added zinc was the one with the
greatest stimulation of proliferation by zinc alone. Initial growth or
some other aspect of growth kinetics may be more important in
modulating the microbicidal effects of the beta-lactams than the total
number of organisms generated during the entire incubation period.
In summary, an effect was found whereby zinc stimulation of bacterial
growth in human empyema fluid enhanced the ability of ampicillin and
cefazolin to kill the growing organisms, whereas the same was not true
for the fluoroquinolone trovafloxacin. This phenomenon appeared to be
isolate and concentration dependent. Thus, zinc may enhance
microbicidal activity by suppressing the microbistatic effect of the
neutrophil protein calprotectin and increasing growth. Antibiotics that
do not depend as much on growth for their killing activity, such as the
fluoroquinolone trovafloxacin, apparently are not subject to this
effect. It is possible that with certain bacterial isolates and
antibiotic concentrations, drugs of the fluoroquinolone class may show
better microbicidal activity in abscess fluids than do beta-lactams.
 |
ACKNOWLEDGMENTS |
This work was supported by Pfizer, Inc., and the Department of
Veterans Affairs.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Research
Service/151, V.A. Medical Center, Milwaukee, WI 53295. Phone: (414)
384-2000, ext. 2878. Fax: (414) 383-8010. E-mail:
psohnle{at}mcw.edu.
 |
REFERENCES |
| 1.
|
Bamberger, D. M.,
K. M. Bettin, and D. N. Gerding.
1987.
Neutrophil localization in acute and chronic experimental abscesses.
J. Lab. Clin. Med.
109:389-395[Medline].
|
| 2.
|
Bamberger, D. M., and B. L. Herndon.
1990.
Bactericidal capacity of neutrophils in rabbits with experimental acute and chronic abscesses.
J. Infect. Dis.
162:186-192[Medline].
|
| 3.
|
Bamberger, D. M.,
B. L. Herndon, and P. R. Suvarna.
1993.
The effect of zinc on microbial growth and bacterial killing by cefazolin in a Staphylococcus aureus abscess milieu.
J. Infect. Dis.
168:893-896[Medline].
|
| 4.
|
Bryant, R. E., and J. A. Mazza.
1989.
Effect of the abscess environment on the antimicrobial activity of ciprofloxacin.
Am. J. Med.
87(Suppl. 5A):23S-27S[Medline].
|
| 5.
|
Clohessy, P. A., and B. E. Golden.
1995.
Calprotectin-mediated zinc chelation as a biostatic mechanism in host defence.
Scand. J. Immunol.
42:551-556[CrossRef][Medline].
|
| 6.
|
Fagerhol, M. K.,
K. B. Andersson,
C. F. Naess-Andresen,
P. Brandtzaeg, and I. Dale.
1990.
Calprotectin (the L1 protein), p. 187-210.
In
V. L. Smith, and J. R. Dedman (ed.), Stimulus response coupling: the role of intracellular calcium-binding proteins. CRC Press, Boca Raton, Fla
|
| 7.
|
Finkelstein, R. A.,
C. V. Sciortino, and M. A. McIntosh.
1983.
Role of iron in microbe-host interactions.
Rev. Infect. Dis.
5:S759-S777.
|
| 8.
|
Girard, A. E.,
D. Girard,
T. D. Gootz,
J. A. Faiella, and C. R. Cimochowski.
1995.
In vivo efficacy of trovofloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumonia, and Bacteroides fragilis.
Antimicrob. Agents Chemother.
39:2210-2216[Abstract].
|
| 9.
|
Hindler, J. (ed.).
1992.
Antimicrobial susceptibility testing, p. 5.0.1-5.25.1.
In
H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
|
| 10.
|
Kenny, P. A.,
L. K. Spencer,
P. J. McDonald, and J. J. Finlay-Jones.
1990.
Functional activity of individual abscess neutrophils from mice.
Infect. Immun.
58:4004-4010[Abstract/Free Full Text].
|
| 11.
|
Lepper, M. H., and H. F. Dowling.
1951.
Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin.
Arch. Intern. Med.
88:489-496[Abstract/Free Full Text].
|
| 12.
|
McNamara, M. P.,
J. H. Wiessner,
C. Collins-Lech,
B. L. Hahn, and P. G. Sohnle.
1988.
Neutrophil death as a defense mechanism against Candida albicans infections.
Lancet
ii:1163-1165.
|
| 13.
|
Miyasaki, K. T.,
A. L. Bodeau,
A. R. K. Murthy, and R. I. Lehrer.
1993.
In vitro antimicrobial activity of the human neutrophil cytosolic S-100 protein complex, calprotectin, against Capnocytophaga sputigena.
J. Dent. Res.
72:517-523[Abstract/Free Full Text].
|
| 14.
|
Polk, H. C., Jr., and D. E. Fry.
1981.
Infection and fever in the surgical patient, p. 1-19.
In
J. D. Hardy (ed.), Complications in surgery and their management. W. B. Saunders, Philadelphia, Pa
|
| 15.
|
Santhanagopalan, V.,
B. L. Hahn,
B. Dunn,
J. H. Wiessner, and P. G. Sohnle.
1995.
Antimicrobial activity of calprotectin isolated from human empyema fluid supernatants.
Clin. Immunol. Immunopathol.
76:285-290[CrossRef][Medline].
|
| 16.
|
Santhanagopalan, V.,
B. L. Hahn, and P. G. Sohnle.
1995.
Resistance of zinc-supplemented Candida albicans yeast cells to the growth-inhibitory effect of calprotectin.
J. Infect. Dis.
171:1289-1294[Medline].
|
| 17.
|
Sohnle, P. G.
1997.
Antimicrobial defence through competition for zinc.
Rev. Med. Microbiol.
8:217-224.
|
| 18.
|
Sohnle, P. G.,
C. Collins-Lech, and J. H. Wiessner.
1991.
Antimicrobial activity of an abundant calcium-binding protein in the cytoplasm of human neutrophils.
J. Infect. Dis.
163:187-192[Medline].
|
| 19.
|
Sohnle, P. G.,
C. Collins-Lech, and J. H. Wiessner.
1991.
The zinc-reversible antimicrobial activity of neutrophil lysates and abscess fluid supernatants.
J. Infect. Dis.
164:137-142[Medline].
|
| 20.
|
Sohnle, P. G.,
B. L. Hahn, and V. Santhanagopalan.
1996.
Inhibition of Candida albicans growth by calprotectin in the absence of direct contact with the organisms.
J. Infect. Dis.
174:1369-1372[Medline].
|
| 21.
|
Steinbakk, M.,
C. F. Naess-Andresen,
E. Lingass,
I. Dale,
P. Brandtzaeg, and M. K. Fagerhol.
1990.
Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin.
Lancet
336:763-765[CrossRef][Medline].
|
| 22.
|
Stevens, D. L.,
A. E. Gibbons,
R. Bergstrom, and V. Winn.
1988.
The Eagle effect revisited efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.
J. Infect. Dis.
158:23-28[Medline].
|
| 23.
|
Stevens, D. L.,
M. H. Tanner,
J. Winship,
R. Swarts,
K. M. Ries,
P. M. Schlievert, and E. Kaplan.
1989.
Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West severe group A streptococcal infections associated with a toxic shock-like syndrome.
N. Engl. J. Med.
321:1-7[Abstract].
|
| 24.
|
Stevens, D. L.,
S. Yan, and A. E. Bryant.
1993.
Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo an explanation for the inoculum effect.
J. Infect. Dis.
167:1401-1405[Medline].
|
| 25.
|
Weinberg, E. D.
1975.
Nutritional immunity host's attempt to withhold iron from microbial invaders.
JAMA
231:39-41[Abstract/Free Full Text].
|
| 26.
|
Zeiler, H. J., and K. Grohe.
1984.
The in vitro and in vivo activity of ciprofloxacin.
Eur. J. Clin. Microbiol.
3:339-343[CrossRef][Medline].
|
Antimicrobial Agents and Chemotherapy, January 2000, p. 139-142, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Champaiboon, C., Sappington, K. J., Guenther, B. D., Ross, K. F., Herzberg, M. C.
(2009). Calprotectin S100A9 Calcium-binding Loops I and II Are Essential for Keratinocyte Resistance to Bacterial Invasion. J. Biol. Chem.
284: 7078-7090
[Abstract]
[Full Text]
-
Rahman, M. J, Sarker, P., Roy, S. K, Ahmad, S. M, Chisti, J., Azim, T., Mathan, M., Sack, D., Andersson, J., Raqib, R.
(2005). Effects of zinc supplementation as adjunct therapy on the systemic immune responses in shigellosis. Am. J. Clin. Nutr.
81: 495-502
[Abstract]
[Full Text]